• If you are wondering whether Vera Therapeutics at around US$38.86 is priced purely on its story or still leaves some value on the table, this article walks through what the current share price actually implies.
• The stock has had a mixed run, with a 4.1% decline over the past week and a 4.7% decline over the past month, yet it still shows a 45.9% return over the last year and a very large return over three years.
• Recent attention on Vera Therapeutics has focused on its position in the biotech space and how the market is weighing its clinical and pipeline prospects against execution and funding risks. This backdrop helps explain why returns year to date show a 20.1% decline even as the three-year performance is very large.
• On Simply Wall St's 6 point valuation checklist, Vera Therapeutics scores 3 out of 6. You can see the detailed breakdown in the valuation score. Next comes a look at how different valuation methods frame the current price and why a more complete way of thinking about value at the end of this article could matter even more.

Approach 1: Vera Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of a company’s future cash flows and discounts them back to today, aiming to translate those projections into a single estimated value per share.

For Vera Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about US$241.7 million. Analyst estimates and extrapolations then map out cash flows over the next decade, moving from projected annual losses in the next few years to a projected free cash flow of about US$450.5 million in 2030, with later years based on Simply Wall St growth assumptions.

When all of those projected cash flows are discounted back using this framework, the estimated intrinsic value comes out at roughly US$338.10 per share. Against a current share price around US$38.86, the model suggests the stock trades at an 88.5% discount to that intrinsic value, which screens as materially undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vera Therapeutics is undervalued by 88.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Vera Therapeutics Price vs Book

For companies that are not yet generating positive earnings or meaningful revenue, price-based multiples tied to the balance sheet, such as Price to Book, are often the most practical way to think about valuation. You are essentially comparing what investors pay in the market for each dollar of net assets on the balance sheet.

In general, higher growth expectations or lower perceived risk can support a higher “normal” P/B multiple. Weaker outlooks or higher uncertainty tend to be associated with lower P/B levels. Against that backdrop, Vera Therapeutics currently trades around 4.59x book value, compared with the Biotechs industry average of about 2.22x and a peer group average of roughly 5.32x, so the stock sits above the broad industry but below closer peers.

Simply Wall St’s Fair Ratio is a proprietary version of the preferred multiple that aims to reflect what multiple might be reasonable after accounting for Vera Therapeutics’ earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it adjusts for these company specific inputs, it is intended to be more informative than a simple comparison with peers or the industry average alone. In this case, the Fair Ratio is not available, so no additional conclusion can be drawn beyond the raw P/B comparisons.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Vera Therapeutics Narrative

Earlier it was mentioned that there is an even better way to think about valuation, so meet Narratives, a simple way for you to attach a clear story about Vera Therapeutics to your numbers such as fair value, and your expectations for future revenue, earnings and margins.

A Narrative links what you believe about the company, for example its pipeline potential or funding risks, to a financial forecast and then to a fair value that you can directly compare with the current share price to help inform whether you might buy, hold or sell.

On Simply Wall St, Narratives sit in the Community page, are quick to set up, are used by millions of investors, and are automatically refreshed when new information such as news, clinical updates or earnings is added to the platform so your view stays aligned with the latest data.

For Vera Therapeutics, one investor might build a Narrative that assumes a relatively cautious fair value and slower revenue progress, while another assumes a higher fair value and stronger revenue growth. You can see both side by side to decide which story feels more reasonable to you.

Do you think there's more to the story for Vera Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.